

Xiaojun Feng

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8292861/xiaojun-feng-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

466
citations

11
h-index

17
g-index

17
ext. papers

709
ext. citations

7
avg, IF

4.04
L-index

#	Paper	IF	Citations
17	Free fatty acid receptor 2 promotes cardiomyocyte hypertrophy by activating STAT3 and GATA4. <i>Food Science and Human Wellness</i> , 2022 , 11, 405-417	8.3	0
16	Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. <i>Theranostics</i> , 2021 , 11, 9376-9396	12.1	6
15	Metformin, Macrophage Dysfunction and Atherosclerosis. <i>Frontiers in Immunology</i> , 2021 , 12, 682853	8.4	10
14	Natural products: The role and mechanism in low-density lipoprotein oxidation and atherosclerosis. <i>Phytotherapy Research</i> , 2021 , 35, 2945-2967	6.7	12
13	Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function. <i>Frontiers in Pharmacology</i> , 2020 , 11, 635	5.6	14
12	The lncRNA-GAS5/miR-221-3p/DKK2 Axis Modulates ABCB1-Mediated Adriamycin Resistance of Breast Cancer via the Wnt/ECatenin Signaling Pathway. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 19, 1434-1448	10.7	52
11	SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity. <i>Aging</i> , 2020 , 12, 4178-4192	5.6	11
10	ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. <i>Progress in Lipid Research</i> , 2020 , 77, 101006	14.3	48
9	Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. <i>Theranostics</i> , 2019 , 9, 1923-1951	12.1	123
8	Danhong injection in cardiovascular and cerebrovascular diseases: Pharmacological actions, molecular mechanisms, and therapeutic potential. <i>Pharmacological Research</i> , 2019 , 139, 62-75	10.2	51
7	Hydrogen Sulfide (HS)-Releasing Compounds: Therapeutic Potential in Cardiovascular Diseases. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1066	5.6	47
6	SIRT6 suppresses phenylephrine-induced cardiomyocyte hypertrophy through inhibiting p300. <i>Journal of Pharmacological Sciences</i> , 2016 , 132, 31-40	3.7	19
5	STAT3 Suppression Is Involved in the Protective Effect of SIRT6 Against Cardiomyocyte Hypertrophy. <i>Journal of Cardiovascular Pharmacology</i> , 2016 , 68, 204-14	3.1	19
4	RIP140 triggers foam-cell formation by repressing ABCA1/G1 expression and cholesterol efflux via liver X receptor. <i>FEBS Letters</i> , 2015 , 589, 455-60	3.8	7
3	Tumor suppressor gene ING3 induces cardiomyocyte hypertrophy via inhibition of AMPK and activation of p38 MAPK signaling. <i>Archives of Biochemistry and Biophysics</i> , 2014 , 562, 22-30	4.1	10
2	The p65 subunit of NF- κ B involves in RIP140-mediated inflammatory and metabolic dysregulation in cardiomyocytes. <i>Archives of Biochemistry and Biophysics</i> , 2014 , 554, 22-7	4.1	14
1	COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: role of NFATc3. <i>Molecular and Cellular Endocrinology</i> , 2014 , 382, 998-1006	4.4	23

